[PMH32] Cost of schizophrenia in France

[PMH32] Cost of schizophrenia in France

2009 Value in health

Heider, D. | Angermeyer, M.C. | Millier, A. | Konig, H.H. | Azorin, J.M. | Toumi, M. | Volume: 12, Issue: 7, Pages: A356, poster, Schizophrenia, France,

OBJECTIVES: The main objective is to assess resource utilization and cost of schizophrenia
as well as cost drivers using a prospective cohort that followed a representative
sample of 288 French patients. METHODS: This study is the first comprehensive
prospective study on cost of schizophrenia. Patients were randomly selected from three
defined catchment areas located in the North, Centre and South of France. Unit costs
were based on the most valid available data, mainly health insurance and French
public sources. Costs were defined based on society perspective. Direct cost included
treatment provided in inpatient services, intermediate facilities, outpatient visits and
medication costs. Indirect costs were considered as productivity loss for unemployed
or sick leave patients in working age. RESULTS: Average patient direct costs yield
a3534, break down as 39.3% for inpatient treatment, 37.7% for day clinic, and
16.1% for medication. The remaining includes visits to psychiatrists, GP’s, psychologists
and other physicians. Assuming 1% prevalence of schizophrenia, the estimation
of annual direct costs yields a1, 581, 111, 600, and indirect cost of schizophrenia
linked to productivity loss in France yields a2, 214, 488, 006. Several cost drivers
were identified: relapse during the follow-up period, positive symptoms of schizophrenia,
and depressive symptoms at baseline predict higher costs, while satisfaction with
their health or negative symptoms of schizophrenia at baseline was linked with lower
costs. CONCLUSIONS: This study highlights the heavy societal burden of schizophrenia
in France, of which hospitalization (day and full time) services account for 77%.
Any attempt to anticipate and prevent hospitalization might have significant effect on
the cost of schizophrenia. Such intervention is likely to be cost effective.